Dr Lalchandani Labs Ltd
₹ 15.1
-4.97%
02 Mar
- close price
About
Incorporated in 2011, Dr. Lalchandani Labs Ltd is in the business of running laboratories
for pathological investigations[1]
Key Points
- Market Cap ₹ 13.1 Cr.
- Current Price ₹ 15.1
- High / Low ₹ 21.2 / 7.24
- Stock P/E 27.8
- Book Value ₹ 11.7
- Dividend Yield 0.00 %
- ROCE 2.81 %
- ROE 3.08 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -26.0%
- The company has delivered a poor sales growth of -6.11% over past five years.
- Promoter holding is low: 31.2%
- Company has a low return on equity of -7.04% over last 3 years.
- Company might be capitalizing the interest cost
- Earnings include an other income of Rs.0.29 Cr.
- Company has high debtors of 431 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Loading peers table ...
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| 2.79 | 5.26 | 6.10 | 9.78 | 11.28 | 5.04 | 4.81 | 4.45 | 4.38 | |
| 2.17 | 4.06 | 4.84 | 7.54 | 8.81 | 4.95 | 4.59 | 3.52 | 3.61 | |
| Operating Profit | 0.62 | 1.20 | 1.26 | 2.24 | 2.47 | 0.09 | 0.22 | 0.93 | 0.77 |
| OPM % | 22.22% | 22.81% | 20.66% | 22.90% | 21.90% | 1.79% | 4.57% | 20.90% | 17.58% |
| 0.03 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 1.40 | 0.13 | 0.29 | |
| Interest | 0.16 | 0.14 | 0.18 | 0.35 | 0.60 | 0.99 | 0.38 | 0.09 | 0.04 |
| Depreciation | 0.13 | 0.35 | 0.42 | 0.52 | 0.59 | 0.66 | 0.62 | 0.56 | 0.56 |
| Profit before tax | 0.36 | 0.72 | 0.66 | 1.37 | 1.28 | -1.56 | 0.62 | 0.41 | 0.46 |
| Tax % | 25.00% | 26.39% | 28.79% | 26.28% | 28.12% | 0.00% | 0.00% | -2.44% | |
| 0.26 | 0.53 | 0.47 | 1.01 | 0.93 | -1.56 | 0.62 | 0.42 | 0.47 | |
| EPS in Rs | 0.44 | 0.61 | 0.54 | 1.16 | 1.07 | -1.79 | 0.71 | 0.48 | 0.54 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -6% |
| 3 Years: | -27% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -9% |
| 3 Years: | -31% |
| TTM: | -45% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 12% |
| 3 Years: | -12% |
| 1 Year: | 51% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 0% |
| 3 Years: | -7% |
| Last Year: | 3% |
Balance Sheet
Figures in Rs. Crores
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2.93 | 4.33 | 4.33 | 4.33 | 4.33 | 4.33 | 4.33 | 4.33 | 4.33 |
| Reserves | 0.40 | 3.73 | 4.21 | 5.22 | 6.15 | 4.59 | 5.21 | 5.62 | 5.82 |
| 1.88 | 0.90 | 1.76 | 4.04 | 5.15 | 6.40 | 3.48 | 4.07 | 4.58 | |
| 1.00 | 1.18 | 1.63 | 1.61 | 2.49 | 2.40 | 1.97 | 1.72 | 1.36 | |
| Total Liabilities | 6.21 | 10.14 | 11.93 | 15.20 | 18.12 | 17.72 | 14.99 | 15.74 | 16.09 |
| 2.06 | 3.28 | 3.47 | 5.24 | 5.75 | 5.39 | 3.99 | 3.51 | 3.38 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.41 | 0.27 | 0.27 |
| 3.91 | 6.62 | 8.22 | 9.72 | 12.13 | 12.09 | 10.59 | 11.96 | 12.44 | |
| Total Assets | 6.21 | 10.14 | 11.93 | 15.20 | 18.12 | 17.72 | 14.99 | 15.74 | 16.09 |
Cash Flows
Figures in Rs. Crores
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| 0.58 | -0.45 | -0.10 | 1.19 | 2.01 | 0.00 | -0.22 | 0.37 | |
| -1.29 | -1.95 | -0.53 | -2.26 | -1.53 | -0.20 | 1.00 | 0.06 | |
| 1.57 | 3.51 | 0.85 | 1.71 | 0.16 | -0.23 | -1.59 | 0.58 | |
| Net Cash Flow | 0.85 | 1.12 | 0.23 | 0.64 | 0.64 | -0.43 | -0.81 | 1.01 |
Ratios
Figures in Rs. Crores
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 149.14 | 126.99 | 199.25 | 148.54 | 136.55 | 359.93 | 356.65 | 431.44 |
| Inventory Days | 167.03 | 233.36 | 158.70 | 68.75 | 191.07 | 458.51 | 255.15 | 490.47 |
| Days Payable | 426.86 | 406.89 | 355.48 | 97.06 | 175.15 | 404.21 | 217.94 | 365.00 |
| Cash Conversion Cycle | -110.69 | -46.54 | 2.47 | 120.23 | 152.47 | 414.23 | 393.86 | 556.91 |
| Working Capital Days | 162.22 | 167.23 | 206.43 | 104.50 | 77.98 | 188.29 | 163.91 | 156.66 |
| ROCE % | 12.14% | 8.72% | 14.40% | 12.87% | -3.68% | -2.68% | 2.81% |
Insights
In beta| Apr 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Number of Collection Centers Number |
|
||||||
| Number of Self-Sufficient Laboratories Number |
|||||||
| Sample Processing Capacity Samples per hour |
|||||||
Requires Premium
Requires Premium
Documents
Announcements
-
Board Meeting Outcome for Outcome Of Board Meeting Held On Monday March 02, 2026
1d - Allotted 43,04,000 rights shares at ₹10; paid-up capital ₹8,63,70,680; issue Feb 4–27, 2026.
-
Approval Of Basis Of Allotment Under Right Issue
1d - Allotted 43,04,000 shares at ₹10 via rights; raised ₹430.40 lakh; paid-up capital ₹8,63,70,680.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
17 Feb - Newspaper publication for extension of issue closing date and extension of date of on market renunciation of Rights Entitlements.
-
Board Meeting Revised Outcome For Extension Of Issue Period
16 Feb - Rights issue closing extended from Feb 20 to Feb 27; on-market renunciation extended to Feb 24.
-
Board Meeting Outcome for Board Meeting Outcome For Extension Of Issue Period
16 Feb - Rights issue extended from Feb 20 to Feb 27, 2026; allotment Mar 2, listing Mar 5.
Business Overview:[1][2][3]
DLLL is a NABL accredited company with 5 Self-sufficient Labs and 15 collection centers across Delhi/NCR. It is empaneled for CGHS (South, North and East Block), DJB, MCD, DDA etc. and provides diagnostic and related healthcare tests and services. Company owns, runs laboratories for carrying out pathological investigations of various branches of Bio-Chemistry, Hematology, Histopathology, Microbiology, Electrophoresis, Virology, Cytology, other pathological Investigations and Immunoassay, Immuno-Histochemistry, Molecular Pathology, DNA & Genetic Testing etc.